← Search & browse all drugs
SENSORY ORGANS › OTOLOGICALS › CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION › Corticosteroids and antiinfectives in combination
triamcinolone and antiinfectives
S02CA04
Forms & Strengths
- Otic suspension: triamcinolone acetonide 0.05% combined with various anti-infectives (e.g., polymyxin B sulfate, neomycin sulfate, hydrocortisone or thonzonium bromide)
Adult Dosing
- Otic suspension: Instill 3 to 4 drops into the affected external auditory canal 2 to 4 times daily
- Duration of therapy typically should not exceed 10 consecutive days
Pediatric Dosing
- Otic suspension (children > 2 years): Instill 3 drops into the affected external auditory canal 2 to 4 times daily
- Safety and efficacy in infants and very young children are not well established
Indications
- Treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the anti-infective component
- Relief of inflammatory and pruritic manifestations of acute otitis externa
Mechanism of Action
- Triamcinolone acetonide: A potent synthetic corticosteroid providing anti-inflammatory, antipruritic, and vasoconstrictive effects
- Anti-infective components (e.g., neomycin, polymyxin B): Bactericidal action via inhibition of bacterial protein synthesis and disruption of the cell membrane
Contraindications
- Hypersensitivity to triamcinolone, any component of the formulation, or cross-sensitizing aminoglycoside antibiotics
- Viral infections of the external canal including herpes simplex and varicella (chickenpox)
- Fungal otic infections
- Perforated tympanic membrane (due to potential ototoxicity from aminoglycosides)
Adverse Reactions
- Local stinging, burning, irritation, or dryness at the application site
- Allergic contact dermatitis and hypersensitivity reactions
- Superinfection with non-susceptible organisms or fungi with prolonged use
- Ototoxicity (if middle ear exposure occurs through a perforated eardrum)
Drug Interactions
- Systemic absorption from otic administration is minimal, but concurrent use of other systemic or topical aminoglycosides may increase the risk of nephrotoxicity and ototoxicity
- Potent CYP3A4 inhibitors (theoretical systemic interaction, though minimal risk via otic route)
Curated Content: Needs Vetting Before Put to Clinical Use